Literature DB >> 17276397

Functional characterization of a new p53 mutant generated by homozygous deletion in a neuroblastoma cell line.

Yohko Nakamura1, Toshinori Ozaki, Hidetaka Niizuma, Miki Ohira, Takehiko Kamijo, Akira Nakagawara.   

Abstract

p53 is a key modulator of a variety of cellular stresses. In human neuroblastomas, p53 is rarely mutated and aberrantly expressed in cytoplasm. In this study, we have identified a novel p53 mutant lacking its COOH-terminal region in neuroblastoma SK-N-AS cells. p53 accumulated in response to cisplatin (CDDP) and thereby promoting apoptosis in neuroblastoma SH-SY5Y cells bearing wild-type p53, whereas SK-N-AS cells did not undergo apoptosis. We found another p53 (p53DeltaC) lacking a part of oligomerization domain and nuclear localization signals in SK-N-AS cells. p53DeltaC was expressed largely in cytoplasm and lost the transactivation function. Furthermore, a 3'-part of the p53 locus was homozygously deleted in SK-N-AS cells. Thus, our present findings suggest that p53 plays an important role in the DNA-damage response in certain neuroblastoma cells and it seems to be important to search for p53 mutations outside DNA-binding domain.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17276397     DOI: 10.1016/j.bbrc.2007.01.057

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  19 in total

1.  Hsp90 inhibition increases p53 expression and destabilizes MYCN and MYC in neuroblastoma.

Authors:  Paul L Regan; Joshua Jacobs; Gerald Wang; Jaime Torres; Robby Edo; Jennifer Friedmann; Xao X Tang
Journal:  Int J Oncol       Date:  2011-01       Impact factor: 5.650

2.  MYCN concurrence with SAHA-induced cell death in human neuroblastoma cells.

Authors:  Constanza Cortés; Sara C Kozma; Albert Tauler; Santiago Ambrosio
Journal:  Cell Oncol (Dordr)       Date:  2015-08-26       Impact factor: 6.730

Review 3.  Cellular adaptation to hypoxia and p53 transcription regulation.

Authors:  Yang Zhao; Xue-qun Chen; Ji-zeng Du
Journal:  J Zhejiang Univ Sci B       Date:  2009-05       Impact factor: 3.066

4.  Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists.

Authors:  Brian J Lestini; Kelly C Goldsmith; Mark N Fluchel; Xueyuan Liu; Niel L Chen; Bella Goyal; Bruce R Pawel; Michael D Hogarty
Journal:  Cancer Biol Ther       Date:  2009-08-08       Impact factor: 4.742

5.  The p53 isoforms are differentially modified by Mdm2.

Authors:  Suzanne Camus; Sergio Ménendez; Kenneth Fernandes; Nelly Kua; Geng Liu; Dimitris P Xirodimas; David P Lane; Jean-Christophe Bourdon
Journal:  Cell Cycle       Date:  2012-04-15       Impact factor: 4.534

Review 6.  p53: the attractive tumor suppressor in the cancer research field.

Authors:  Toshinori Ozaki; Akira Nakagawara
Journal:  J Biomed Biotechnol       Date:  2010-12-06

7.  Effect of bortezomib on human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicity.

Authors:  Valérie Combaret; Sandrine Boyault; Isabelle Iacono; Stéphanie Brejon; Raphaël Rousseau; Alain Puisieux
Journal:  Mol Cancer       Date:  2008-06-05       Impact factor: 27.401

8.  p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance.

Authors:  Lindi Chen; Deborah A Tweddle
Journal:  Front Oncol       Date:  2012-11-28       Impact factor: 6.244

9.  Complex molecular mechanisms cooperate to mediate histone deacetylase inhibitors anti-tumour activity in neuroblastoma cells.

Authors:  Annick Mühlethaler-Mottet; Roland Meier; Marjorie Flahaut; Katia Balmas Bourloud; Katya Nardou; Jean-Marc Joseph; Nicole Gross
Journal:  Mol Cancer       Date:  2008-06-12       Impact factor: 27.401

10.  NSC-87877 inhibits DUSP26 function in neuroblastoma resulting in p53-mediated apoptosis.

Authors:  Y Shi; I T Ma; R H Patel; X Shang; Z Chen; Y Zhao; J Cheng; Y Fan; Y Rojas; E Barbieri; Z Chen; Y Yu; J Jin; E S Kim; J M Shohet; S A Vasudevan; J Yang
Journal:  Cell Death Dis       Date:  2015-08-06       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.